Learning from the cerivastatin experience
- 1 October 2001
- journal article
- Published by Elsevier in The Lancet
- Vol. 358 (9291) , 1383-1385
- https://doi.org/10.1016/s0140-6736(01)06489-3
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Air force/texas coronary atherosclerosis prevention study (afcaps/texcaps): Additional perspectives on tolerability of long-term treatment with lovastatinThe American Journal of Cardiology, 2001
- Does differing metabolism by cytochrome P450 have clinical importance?Current Atherosclerosis Reports, 2000
- Plasma concentrations of active simvastatin acid are increased by gemfibrozilClinical Pharmacology & Therapeutics, 2000
- Concomitant use of cytochrome P450 3A4 inhibitors and simvastatinThe American Journal of Cardiology, 1999
- Metabolic causes of recurrent rhabdomyolysisActa Neurologica Scandinavica, 1998
- Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol LevelsJAMA, 1998
- Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)Clinical Pharmacokinetics, 1998
- HMG CoA Reductase Inhibitor-Induced Myotoxicity: Pravastatin and Lovastatin Inhibit the Geranylgeranylation of Low-Molecular-Weight Proteins in Neonatal Rat Muscle Cell CultureToxicology and Applied Pharmacology, 1997
- Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatinJournal of Molecular and Cellular Cardiology, 1995
- Plasma coenzyme Q (ubiquinone) concentrations in patients treated with simvastatin.Journal of Clinical Pathology, 1993